Skip to main content
Advertising

Originally published Wednesday, May 1, 2013 at 2:15 PM

  • Share:
           
  • Comments (0)
  • Print

News Summary: Generic rivals hurt Merck results

BAD NEWS: First-quarter sales and net income for Merck & Co. both plunged - 9 percent and 8 percent, respectively - as the world's third-largest drugmaker got slammed by generic competition to multiple drugs. It cut its earnings forecast, sending shares down 3 percent in unusually heavy trading.

The Associated Press

Most Popular Comments
Hide / Show comments
No comments have been posted to this article.
Start the conversation >

advertising

BAD NEWS: First-quarter sales and net income for Merck & Co. both plunged - 9 percent and 8 percent, respectively - as the world's third-largest drugmaker got slammed by generic competition to multiple drugs. It cut its earnings forecast, sending shares down 3 percent in unusually heavy trading.

THE FORECAST: Merck said it expects better results in the second half of the year. It's now expecting 2013 earnings per share of $3.45 to $3.55, 15 cents below its February forecast.

ON DECK: Merck has five drugs under review by regulators, including a promising insomnia medicine called suvorexant.

News where, when and how you want it

Email Icon


Advertising
The Seattle Times

To keep reading, you need a subscription.

We hope you have enjoyed your complimentary access. Subscribe now for unlimited access!

Subscription options ►

Already a subscriber?

We've got good news for you. Unlimited seattletimes.com content access is included with most subscriptions.

Subscriber login ►